MYR GmbH Announces Presentation of Interim Results of Phase 2b C - Erie News Now | WICU & WSEE in Erie, PA

MYR GmbH Announces Presentation of Interim Results of Phase 2b Clinical Program of Myrcludex B at the American Association for the Study of Liver Diseases Conference

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

SOURCE MYR GmbH

MOSCOW, October 4, 2017 /PRNewswire/ --

Hepatera LLC and its development partner MYR GmbH today announced the completion of the 24 weeks active treatment phase in MYR 202 clinical trial, a Phase 2b study investigating Myrcudex B in chronic hepatitis delta infection. 120 subjects have been enrolled into this study in 20 centers in Russia and Germany. The interim data will be presented at the AASLD conference (The Liver Meeting®) in Washington, DC:

Wedemeyer et al., "Interim results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection"; Publication #37, Oral presentation; Parallel Session 5: Hepatitis B: New Therapies, on October 22nd 2017, 10am-10.15am

"The presentation of this interesting data will certainly be very important for the field," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR`s Clinical Advisory Board.

"We hope that the presentation of our results at the one of the largest hepatology gatherings shall further increase attention to the unmet medical need existing in chronic HDV infection," said Alexander Alexandrov, Chief Medical Officer of MYR GmbH. "We are working enthusiastically on our goal to make Myrcludex ? available to these patients who urgently need new therapeutic options as soon as possible."

About Myrcludex B 

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver. Myrcludex B has shown good safety profile and anti-viral activity in animal models and in proof-of-concept clinical trials, has received Orphan Designation for treatment of HDV infection from EMA and FDA, and PRIME scheme eligibility from EMA.

About Hepatera 

"Hepatera" is a private biotech company. The main activity of the company is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. The company's first product, Myrcludex B, is aimed at the treatment of chronic hepatitis B and D. Myrcludex B is being developed in the framework of international cooperation with the biotechnology company MYR, GmbH (Germany).

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections.

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development.

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
WICU FCC Filing
WSEE FCC Filing
Share:
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 - info@wicu12.com